Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | AXL | P30530 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 2/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449738 | 0.97 | KDR (0.46) | KDRCSNK1DCDK4MAPK14AXL | |
| SCHEMBL5453421 | 0.93 | MERTK (0.45) | KDRCSNK1DMAPK14AXLGSK3B | |
| SCHEMBL5457524 | 0.90 | GSK3B (0.46) | MAPK14AXLGSK3BMERTKTYRO3 | |
| SCHEMBL5460142 | 0.89 | GSK3B (0.45) | MAPK14AXLGSK3BMERTKTYRO3 | |
| SCHEMBL5449793 | 0.89 | KDR (0.46) | KDRCSNK1DCDK4MAPK14AXL | |
| SCHEMBL6112342 | 0.88 | KDR (0.41) | KDRCSNK1DCDK4MAPK14AXL | |
| SCHEMBL5464066 | 0.86 | GSK3B (0.43) | MAPK14AXLGSK3BMERTK | |
| SCHEMBL5452168 | 0.85 | GSK3B (0.45) | MAPK14AXLGSK3BMERTKTYRO3 | |
| SCHEMBL6105831 | 0.85 | MERTK (0.43) | KDRCDK4AXLMERTKTYRO3 | |
| SCHEMBL5457474 | 0.85 | GSK3B (0.49) | KDRCSNK1DMAPK14AXLGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | claimed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-7163940-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163940-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | KDR 3259/4885CSNK1D 411/4885CDK4 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.